TFX Teleflex Inc

Arrow® PICC with Chlorag+ard® Technology Shows Greatest Reduction of Thrombus Formation when Compared to Non-Eluting Antithrombogenic Technologies

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, announces the results of a pre-clinical intravascular study, highlighting Arrow® PICC with Chlorag+ard® Technology and its ability to significantly reduce thrombus formation when compared to competitive non-eluting antithrombogenic technologies.

The pre-clinical study titled “Catheter Technologies: Is eluting technology or non-eluting technology more effective in preventing thrombus accumulation?” by Kamna Giare-Patel, MS, et al, evaluated the effectiveness of three types of peripherally inserted central venous catheters (PICCs) with antithrombogenic properties as compared to uncoated PICCs in a clinically simulated ovine model. The three test groups consisted of PICCs with fluorine-based technology (AngioDynamics® BioFlo™ PICC with Endexo™ Technology), chlorhexidine-based technology (Arrow® PICC with Chlorag+ard® Technology) and Amphiphilic PMEA based technology (Terumo® Xcoating™).

After 30 days, all catheters were explanted by dissecting the vessels open. The amount of accumulated thrombus on the catheter surfaces was measured for thrombus weight and length. Arrow® PICC with Chlorag+ard® Technology showed the least amount of thrombus as a result of greatest weight reduction (81%) and length reduction (76%) when compared to the uncoated control catheter. Overall results are in the table below:

                    FLUORINE-   CHLORHEXIDINE-  

 

 

 

PICC GROUP BASED BASED

PMEA-BASED

UNCOATED

    (GROUP A)   (GROUP B)  

(GROUP C)

 

(GROUP D)

Technology Type   Non-eluting   Eluting   Non-eluting   N/A Avg. Weight (g)   0.161   0.066   0.208   0.353 Avg. Length (cm)   4.2   1.7   3.0   7.0 % Weight Reduction (compared to control)   54%   81%   41%   N/A % Length Reduction (compared to control)   40%   76%   57%   N/A  

The authors of the poster concluded that the eluting technology (Arrow® PICC with Chlorag+ard® Technology), compared to the two (2) non-eluting technologies, showed the best outcomes by exhibiting the most effective prevention of thrombus accumulation after a 30-day dwell time. The study was funded by, and authors are employed by, Teleflex Incorporated.

Chlorag+ard® Technology treatment on the external surface of the catheter body as well as the entire fluid pathway of the catheter has been shown to be effective in reducing microbial colonization and thrombus accumulation on catheter surfaces. The Arrow® PICC with Chlorag+ard® Technology offers protection that is designed to reduce the risk of catheter-related occlusion, thrombus accumulation, intimal hyperplasia and catheter colonization for at least thirty (30) days. Additional information may be found at chloragard.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

AngioDynamics, BioFlo and Endexo are trademarks or registered trademarks of AngioDynamics, Inc.

Terumo and Xcoating are trademarks or registered trademarks of Terumo Medical Corporation.

Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, Weck and Chlorag+ard are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

© 2016 Teleflex Incorporated. All rights reserved. MC-001893

View source version on businesswire.com: http://www.businesswire.com/news/home/20160111005005/en/

Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836